{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:35:49Z","timestamp":1790908549881,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41375-024-02372-x","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T08:02:30Z","timestamp":1724140950000},"page":"2162-2170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-515X","authenticated-orcid":false,"given":"Carlo","family":"Gambacorti-Passerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-3723","authenticated-orcid":false,"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian G.","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4752-0815","authenticated-orcid":false,"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-5696","authenticated-orcid":false,"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-489X","authenticated-orcid":false,"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Luscan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Viqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"2372_CR1","unstructured":"Pfizer Inc. Bosulif (bosutinb) prescribing information. 2012. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=884. Accessed 5 Sep 2023."},{"key":"2372_CR2","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376.","journal-title":"Blood"},{"key":"2372_CR3","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119:3403\u201312.","journal-title":"Blood"},{"key":"2372_CR4","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brummendorf TH, Smith BD, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125\u201337.","journal-title":"Leukemia"},{"key":"2372_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood"},{"key":"2372_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27:107\u201312.","journal-title":"Leukemia"},{"key":"2372_CR7","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D Rea","year":"2021","unstructured":"Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341.","journal-title":"Blood"},{"key":"2372_CR8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajh.24423","volume":"91","author":"NP Shah","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91:869\u201374.","journal-title":"Am J Hematol"},{"key":"2372_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617\u201326.","journal-title":"Leukemia"},{"key":"2372_CR10","doi-asserted-by":"publisher","first-page":"e19055","DOI":"10.1200\/JCO.2022.40.16_suppl.e19055","volume":"40","author":"C Gambacorti-Passerini","year":"2022","unstructured":"Gambacorti-Passerini C, Br\u00fcmmendorf TH, Ernst T, Leip E, Purcell S, Viqueira A, et al. Efficacy and safety of bosutinib in later-line patients (pts) with chronic myeloid leukemia (CML): A sub-analysis from the phase 4 BYOND trial. J Clin Oncol. 2022;40:e19055\u2013e.","journal-title":"J Clin Oncol"},{"key":"2372_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106690","volume":"111","author":"V Kota","year":"2021","unstructured":"Kota V, Brummendorf TH, Gambacorti-Passerini C, Lipton JH, Kim DW, An F, et al. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosomepositive leukemias. Leuk Res. 2021;111:106690.","journal-title":"Leuk Res"},{"key":"2372_CR12","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.1200\/JCO.2021.39.15_suppl.7039","volume":"39","author":"MW Deininger","year":"2021","unstructured":"Deininger MW, Br\u00fcmmendorf TH, Milojkovic D, Cervantes F, Huguet F, Viqueira A, et al. Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib. J Clin Oncol. 2021;39:7039.","journal-title":"J Clin Oncol"},{"key":"2372_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2019-127514","volume":"134","author":"F Castagnetti","year":"2019","unstructured":"Castagnetti F, Gugliotta G, Bocchia M, Trawinska MM, Capodanno I, Bonifacio M, et al. Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors. Blood. 2019;134:496.","journal-title":"Blood"},{"key":"2372_CR14","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1182\/blood-2021-151240","volume":"138","author":"S Isfort","year":"2021","unstructured":"Isfort S, Wolf D, Teichmann LL, Crysandt M, Burchert A, Hochhaus A, et al. Step-in dosing in the Bosutinib Dose Optimization Study (BODO) failed to reduce gastrointestinal (GI) toxicity in patients failing second generation TKI (2G-TKI) in chronic phase chronic myeloid leukemia (CML) but suggests promising molecular response. Blood. 2021;138:3608.","journal-title":"Blood"},{"key":"2372_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.HS9.0000845676.81208.c2","volume":"6","author":"F Castagnetti","year":"2022","unstructured":"Castagnetti F, Bocchia M, Abruzzese E, Capodanno I, Bonifacio M, Rege Cambrin G, et al. P698: bosutinib dose optimization in the second-line treatment of elderly CML patients: extended 3-year follow-up and final results of the BEST study. HemaSphere. 2022;6:593\u20134.","journal-title":"HemaSphere"},{"key":"2372_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hon.2851","volume":"39","author":"R Latagliata","year":"2021","unstructured":"Latagliata R, Attolico I, Trawinska MM, Capodanno I, Annunziata M, Elena C, et al. Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant\/intolerant to previous tyrosine-kinase inhibitors. Hematol Oncol. 2021;39:401\u20138.","journal-title":"Hematol Oncol"},{"key":"2372_CR17","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1182\/blood-2021-146175","volume":"138","author":"EJ Jabbour","year":"2021","unstructured":"Jabbour EJ, Deininger MW, Abruzzese E, Apperley JF, Cortes JE, Chuah C, et al. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and optic trials. Blood. 2021;138:2550.","journal-title":"Blood"},{"key":"2372_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1182\/blood-2021-152614","volume":"138","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Jabbour EJ, Issa GC, Naqvi K, Skinner J, Anderson K, et al. Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis. Blood. 2021;138:631.","journal-title":"Blood"},{"key":"2372_CR19","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042\u201350.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02372-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02372-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02372-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T11:06:09Z","timestamp":1727435169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02372-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2372"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02372-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"14 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CG-P: consultancy (Bristol Myers Squibb), honoraria and research funding (Pfizer). THB: research funding (Bristol Myers Squibb, Novartis, Pfizer, Repeat Diagnostic); honoraria (Janssen, Novartis, Pfizer, Takepart Media); consultancy (Pfizer). EA: consultancy and honoraria (Bristol Myers Squibb, Incyte, Novartis, Pfizer). KRK: consultancy (Amgen, AstraZeneca, Denovo Biopharma, Sanofi-Aventis, Takeda, Verastem); equity holder (Agios, Berkley Lights); Speakers Bureau (Bayer, Celgene, Epizyme, Gilead, Janssen, Karyopharm, Novartis, Pharmacyclics). VGO: research funding and lectures (Pfizer); consultancy (Pfizer, Novartis, Ascentage, Terns); honoraria (OncLive). VG-G: research funding (Pfizer, Novartis, BMS, Incyte); consultancy (Bristol Myers Squibb, Incyte, Novartis). HH-H: research funding and lectures (AOP, Incyte, Pfizer).TE: research support from Bristol Myers Squibb, Incyte, Novartis, and Pfizer. EL, SP, GL, AV: employee (Pfizer); equity holder (Pfizer). FJG: consultancy (Novartis). AH: research funding (Bristol Myers Squibb, Incyte, Novartis, Pfizer).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research is in accordance with the Declaration of Helsinki. This study did not use a central ethics committee, rather, separate ethics committees at each study site reviewed and approved the protocol. Informed consent was obtained from all participants before study procedures began.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}